MaxCyte (MXCT) to Release Quarterly Earnings on Tuesday

MaxCyte (NASDAQ:MXCT) will be posting its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect MaxCyte to post earnings of ($0.14) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings results on Tuesday, March 12th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. MaxCyte had a negative net margin of 91.85% and a negative return on equity of 15.90%. The business had revenue of $15.67 million during the quarter, compared to the consensus estimate of $15.60 million. On average, analysts expect MaxCyte to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MaxCyte Stock Performance

Shares of MXCT stock opened at $3.66 on Tuesday. The firm’s 50 day moving average price is $4.19 and its two-hundred day moving average price is $4.34. MaxCyte has a 52-week low of $2.45 and a 52-week high of $5.55. The stock has a market cap of $382.10 million, a PE ratio of -9.89 and a beta of 1.34.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. William Blair reaffirmed an “outperform” rating on shares of MaxCyte in a research note on Wednesday, March 13th. BTIG Research decreased their target price on MaxCyte from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, March 13th. Finally, Stephens reiterated an “overweight” rating and issued a $11.00 price target on shares of MaxCyte in a research report on Tuesday, April 23rd.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.